莱卡内马布治疗后皮层缩:两个截然不同的病例
Kazuto Katsuse1,2,3, Kazuo Kakinuma1, Yoshiki Niimi2,4,5
1Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan.
The Clinical neuropsychologist
|November 19, 2025
概括
对于后皮层缩 (PCA) 的莱卡内马布治疗显示出不同的结果. 由于PCA的异质性和混合病理的可能性,仔细选择患者和量身定制的评估至关重要.
科学领域:
- 神经学 神经学
- 临床神经科学 临床神经科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 后皮层缩 (PCA) 是一种神经退行性综合征.
- 莱卡涅马布是一种针对阿尔茨海默氏症的粉样蛋白向疗法,已获得批准.
- 莱卡尼马布在PCA中的疗效和安全性尚未得到充分证实.
研究的目的:
- 评估lecanemab治疗在PCA中的临床影响,局限性和风险.
- 为了比较两个符合lecanemab资格标准的PCA患者的治疗结果.
主要方法:
- 对两名经生物标志物确认的PCA患者的回顾性分析.
- 对临床病史,神经心理测试,成像和一年内的结果进行审查.
- 对lecanemab资格标准的评估 申请PCA.
主要成果:
- 患者1 (早期发病,左主导性缩) 尽管出现了一些下降,但功能稳定.
- 患者2 (晚期发病,右主导性缩) 经历了帕金森症,幻觉和快速衰退,导致停止治疗.
- 患者对治疗的满意度在患者之间有显著差异.
结论:
- 标准阿尔茨海默病标准可能不适合PCA治疗资格.
- 对于PCA,需要进行特定的视觉认知评估,并考虑表型异质性.
- 同时存在的病理可能会影响治疗反应,需要采用多式联络,量身定制的方法.
相关概念视频
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K


